Harmaline Tremor: Underlying Mechanisms in a Potential Animal Model of Essential Tremor

Adrian Handforth

1 Neurology Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States of America

Abstract

Background: Harmaline and harmine are tremorogenic β-carbolines that, on administration to experimental animals, induce an acute postural and kinetic tremor of axial and truncal musculature. This drug-induced action tremor has been proposed as a model of essential tremor. Here we review what is known about harmaline tremor.

Methods: Using the terms harmaline and harmine on PubMed, we searched for papers describing the effects of these β-carbolines on mammalian tissue, animals, or humans.

Results: Investigations over four decades have shown that harmaline induces rhythmic burst-firing activity in the medial and dorsal accessory inferior olivary nuclei that is transmitted via climbing fibers to Purkinje cells and to the deep cerebellar nuclei, then to brainstem and spinal cord motoneurons. The critical structures required for tremor expression are the inferior olive, climbing fibers, and the deep cerebellar nuclei; Purkinje cells are not required. Enhanced synaptic norepinephrine or blockade of ionic glutamate receptors suppresses tremor, whereas enhanced synaptic serotonin exacerbates tremor. Benzodiazepines and muscimol suppress tremor. Alcohol suppresses harmaline tremor but exacerbates harmaline-associated neural damage. Recent investigations on the mechanism of harmaline tremor have focused on the T-type calcium channel.

Discussion: Like essential tremor, harmaline tremor involves the cerebellum, and classic medications for essential tremor have been found to suppress harmaline tremor, leading to utilization of the harmaline model for preclinical testing of antitremor drugs. Limitations are that the model is acute, unlike essential tremor, and only approximately half of the drugs reported to suppress harmaline tremor are subsequently found to suppress tremor in clinical trials.

Keywords: Tremor, harmaline, harmine, inferior olive, cerebellum, animal model

Introduction

Harmaline induces action tremor in mammals, and as an easily elicited model has attracted increasing interest from workers searching for new therapies for essential tremor (ET). In view of this interest, we review what is known about harmaline’s actions. We describe the model and review the anatomy and physiology of the olivocerebellar circuitry underlying harmaline tremor. We consider proposed mechanisms by which harmaline produces tremor and survey the pharmacology of harmaline tremor. We discuss the limitations of the model and consider how well harmaline predicts drug efficacy for ET.

Methods

We surveyed literature obtained via PubMed using the search words “harmaline” and “harmine”, examining papers describing mechanisms, properties, or tremor. We also consulted related papers on cerebellum physiology and ET. Only a fraction of these publications could be cited.

Results

β-Carbolines

The basic structure of β-carboline alkaloids is similar to tryptamine, a two-ring indole, but the ethylamine side chain is reconnected to the...
indole via a carbon atom, forming a third ring. β-Carboline structures differ according to the degree of saturation of the third ring, the third ring side chain, and the side chains on the benzene ring (Figure 1).

Nutritionally the main source of β-carbolines is animal protein, but they are also found in cereals, corn, beverages (wine, whiskey, beer, sake), and in tobacco.1 β-Carboline structures are also formed endogenously from the condensation of tryptophan-derived indolealkylamines with simple aldehydes or with pyruvic acid. Thus some β-carbolines, such as harmaline and norharman, are normal constituents of human tissue. Because ethanol is converted to aldehyde in tissues and in the stomach,2 a question is whether alcohol ingestion elevates β-carbolines levels. Rats chronically administered alcohol display elevated plasma and brain norharman,3 but no change in brain or lung harmaline.4 In humans, elevated plasma norharman is associated with heavy smoking rather than alcohol intake.5

The rate of elimination also affects β-carboline levels. In humans, CYP 1A2 and 2D6 are the major cytochrome enzymes metabolizing harmaline and harmine, converting these by O-demethylation to non-tremorogenic harmalol and harmol.5 Human Purkinje cells express 2D6, and this expression is upregulated in alcoholics.7 Smoking also increases 2D6 expression in the human brain, as does nicotine administration in animals.8 Cytochrome 2D6 may play a role in defending against β-carboline derivatives that have potential 1-methyl-4-phenylpyridine (MPP⁺)-like neurotoxicity. Endogenous tetrahydro-β-carbolines can undergo methylation by N-methyltransferases to form N(2)-methyl- and N(2,9)-dimethyl-tetrahydro-β-carbolines, which are similar to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).9 Such compounds are found in rat brain and are oxidized by heme oxidases to the corresponding β-carbolineum, structurally analogous to MPP⁺, and similarly neurotoxic. N(2)- and N(9)-methylnorharmanium ions induce bradykinesia and dopamine loss in mice.10 As an alternative to forming β-carbolinium products, N-methylated β-carbolines are removed by CYP 2D6, at a rate highly dependent on the 2D6 polymorphism subtype.11

Such observations have led to speculation that brain 2D6 may protect against neurotoxins derived from β-carbolines or other toxins, in view of evidence that smoking protects against Parkinson’s and ET.13 However, persons who inherit a 2D6 polymorphism with low activity have an inconsistent or weak increase in risk for Parkinson’s disease.14

Do β-carbolines cause ET? ET patients have higher harmaline blood levels, especially in familial cases,17 which is not due to higher dietary intake.18 Harmaline in high doses may cause tremor,17 or do so via a metabolite, harmine. A role of harmaline could also be from tissue damage that gives rise to tremor. Indeed, among ET patients, blood harmaline levels are significantly correlated with the decline in a spectroscopic magnetic resonance imaging measure of viable neurons in the cerebellar cortex.19

**Harmaline tremor: an acute model**

The harmala alkaloids harmine, harmaline, and tetrahydroharmine are especially rich in the seeds of *Peganum harmala* (Syrian Rue) and in the *Banisteriopsis caapi* vine. Extracts from the latter are combined with leaves from *Psychotria viridis*, containing dimethyltryptamine (DMT), to create the ayahuasca sacramental beverage used in shamanic rituals. The principal purpose of the harmala compounds is to inactivate gastrointestinal monoamine oxidase (MAO-A), enabling enough DMT to elude first-pass metabolism so as to produce cognitive/affective effects. The amount of harmala alkaloids absorbed may be small or negligible.19 Large doses of harmine or preparations of *B. caapi* induce in human volunteers a transient coarse tremor.20

Among β-carbolines, ibogaine, harmaline and harmine are especially tremorogenic. Of these, harmaline (7-methoxy-3,4-dihydro-β-carboline) has been most frequently utilized experimentally, but harmaline acts similarly, and similar doses are employed. Harmaline produces an 8–16 Hz tremor in mice,21 rats, cats,22 and monkeys.23 The tremor involves appendicular and axial musculature during posture and kinesia. In a mouse or rat the tremor visibly involves all four limbs, the tail, trunk, and head, including whiskers. The tremor is particularly visible when the animal ambulates, and is less when it lies down.

The peak tremor frequency varies according to the species, ranging from 8–10 Hz in monkey to 11–14 Hz in mice.24 After subcutaneous

---

**Figure 1. β-Carboline Structures.** Harmaline and harmine are used in animal models of tremor. Harmaline, found in human tissue, can be converted to harmine.
or intraperitoneal injection, tremor develops within minutes and lasts up to several hours before subsiding. Tremor may be assessed with rating scales, electromyographic recordings, or digitally quantified with systems that detect motion through force or magnetic field transduction. Because harmaline-induced tremor is an action tremor, the amount of tremor will vary according to the motor activity level. This source of variation can be greatly reduced by normalizing the data to overall motion.

Whole-body tremor is dose-dependent with harmaline doses at 4 mg and above in rats. Doses of 10–20 mg/kg are frequently employed in rats; mice require approximately twice that. If rats are trained to press a disk connected to a transducer, forelimb tremor can be detected at a dose as low as 1.0 mg/kg.

Repeated daily administration of harmaline to rats, 4–16 mg/kg, results in a loss of the tremor response (tolerance) after three to seven treatments, lasting at least 7–10 days. In contrast, tolerance is not observed with four daily doses of a low dose at 1.0 mg/kg or if tremor is prevented with diazepam or morphine during the initial exposure. Mice also develop harmaline tolerance.

Inferior olive (IO) neurons in tolerant rats fail to show harmaline-associated sustained rhythmic activity; and vermal Purkinje neurons do not show expected rhythmic climbing fiber responses, suggesting that tolerance may reflect physiological changes.

Another explanation for tolerance may be neuronal damage, but rats and mice show different morphological alterations after harmaline. In rats, harmaline causes Purkinje neuron loss in narrow parasagittal vermis zones, possibly due to excitotoxic climbing fiber hyperactivity. The IO is unaffected. In contrast, mice show no cell loss or gliosis in the cerebellar cortex but instead show microglosis in IO without cell loss, with the medial and dorsal accessory regions most affected.

The anatomic and physiologic basis of harmaline tremor

Harmaline activates circuits within the olivocerebellar system to produce tremor. Before discussing this circuitry we briefly review selected aspects of olivocerebellar physiology.

Normal olivocerebellar system functioning

**Subthreshold oscillation.** IO neurons in brainstem slices normally demonstrate rhythmic membrane voltage subthreshold oscillations (STOs) that involve serial ion conductances. A high threshold calcium spike is followed by a depolarizing shoulder that is terminated by a potassium conductance that leads to an afterhyperpolarization, which in turn deactivates a low-threshold (T-type) calcium current. That causes a rebound spike which triggers the high-threshold calcium spike, and may or may not be enough to trigger a sodium spike. The oscillation frequency is approximately 10 Hz, whereas individual IO cells fire at 1 Hz. Spontaneous STOs are suppressed by apamin, serotonin via 5HT2a receptors, NMDA receptor antagonists, and L-, P-, and T-type calcium channel blockers.

STOs are synchronized among ensembles of IO neurons via electrical coupling. Hundreds of IO neurons oscillate coherently in discrete clusters, with moment-to-moment variation in cluster size. Addition of picrotoxin, a GABA<sub>A</sub> receptor antagonist, induces clusters to merge, forming larger units. IO neurons form dendritic tangles (glomeruli) containing abundant gap junctions. Addition of a gap junction blocker disrupts synchrony. GABAergic afferents terminate near gap junctions, where they can control electrotonic coupling.

**IO–Purkinje ensembles.** IO neurons project climbing fibers to Purkinje cell dendrites, with collaterals to deep cerebellar nuclei (DCN) non-GABAergic and GABAergic neurons. Purkinje cells respond to climbing fibers with complex spikes, whereas parallel fibers from granule cells mediate simple spikes. Because each Purkinje cell receives a single climbing fiber from a dedicated IO neuron, the behavior of multiple IO neurons in vivo can be studied by recording complex spikes from many Purkinje cells simultaneously. Such studies reveal that Purkinje cell firing is synchronized at 10 Hz within small vertical cortical bands, indicating that they are controlled by electrically coupled IO ensembles. The intra-band synchrony and band size, and by inference that of the projecting IO ensemble, are not fixed but modulated by afferents to IO. Intra-IO picrotoxin injection or lesions of the dentate nucleus, which projects GABA to the IO, increases Purkinje cell within-band synchrony and synchronous band width. Glutamate also modulates IO/Purkinje synchrony. Intra-IO injection of 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoline-7-sulfonamide (NBQX), an α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor antagonist, disrupts IO/Purkinje synchrony. Intra-IO injection of 5-amino-3-hydroxy-4-(3-(trifluoromethyl)phenyl)imidazol-2-yl)tetrahydrofuran-2-carboxamide (CP-73,431), an AMPA receptor agonist, increases IO/Purkinje synchrony. Intra-IO injection of 5-methyl-6-(phenylsulfanyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (RD-3442), a calcium channel blocker, disrupts IO/Purkinje synchrony.
acid (AMPA) receptor antagonist, reduces synchronous Purkinje cell band width, indicating that glutamate expands synchrony in the IO. 58

In summary, IO neurons do not fire often, but when they do, the timing is precisely timed according to the depolarization phase of STOs that are tightly synchronized within an IO ensemble. The aggregate firing is thus highly rhythmic. The IO ensembles are not fixed, but sculpted on a moment-to-moment basis. 19 IO gap junctions and the activity of DCN that control IO coupling via GABA projections play critical roles.

**Gap junctions.** IO neurons richly express the gap junction protein connexin 36 (Cx36). 41 Cx36-null mice appear to lack IO gap junctions, 50 and IO slices show rare and weak electrical coupling, so that IO STOs and action potentials are not synchronized. 51 Loss of IO coupling also occurs with transduction of inactive mutant Cx36 and the addition of the gap junction blocker carbenoxolone. 52, 53 Purkinje cell complex spike synchrony is lost in mice receiving intra-IO carbenoxolone injection and in Cx36-null mice. 54, 55

**Deep cerebellar nuclei.** DCN neurons send excitatory efferents to extracerebellar structures and a massive GABAergic projection to the IO. Climbing fibers are excitatory and send collaterals to GABAergic DCN neurons, which are coupled with Cx36 gap junctions, 41 and project back to IO, and to non-GABAergic DCN neurons. Climbing fiber-activated Purkinje cells project GABAergic terminals to both DCN non-GABA (glutamate) and GABAergic neurons. 56

GABA DCN neurons show strong rebound discharges after AHP, due to Cav3.1 T-type channels, 57 compatible with phasic firing, in which timing rather than intensity modulation is important. 58 In contrast, large non-GABA DCN neurons express a linear firing-to-stimulation relationship, functioning as a linear transducer of spike frequency, suitable as output neurons. These neurons express weaker rebound discharges, 58 and may correspond to excitatory neurons observed not to express Cav3.1 T-type channels. 57

**What happens to this system when harmaline is administered?** When harmaline is added to the brainstem slice, IO neurons exhibit increased rebound low threshold (T-type) calcium spikes, so that each rebound is now associated with bursts of sodium action potentials. Thus the IO neurons are made more excitable by harmaline and convert from STO to rhythmic 9–12 Hz burst-firing. 36, 37 In animals, IO harmaline microinjection elicits rhythmic local bursting only when the medial accessory olive (MAO) and dorsal accessory olive (DAO) are injected. 59 Intravenous harmaline in cats causes IO neurons confined to MAO and DAO to fire rhythmically and synchronously at 6–12 Hz, generating rhythmic Purkinje cell complex spikes, whereas simple spikes are suppressed. 72 In addition, neurons in DCN, lateral reticular nucleus, red nucleus, nucleus reticularis tegmenti pontis, spinal cord interneurons, and motoneurons also fire at the tremor frequency. 60, 61 In cat, harmaline increases glucose utilization in the MAO, caudolateral DAO, the molecular layer of the vermis and paravermis cerebellar cortex, and the same three brainstem nuclei shown to fire at the tremor frequency. 62 For mapping demonstrates IO activation 15 minutes after harmaline administration, followed by DCN at 30 minutes, cerebellar cortex at 1 hour, and vertical bands of vermal Purkinje cells at 2–6 hours. 63 The delay in DCN recruitment has also been found with field potential recordings. 64

The harmaline-responsive Purkinje cells are mainly found in the vermis and paravermis regions in the rat and cat, 65 to which MAO and DAO project. These cortical regions project to the fastigial and interpositus DCN, which also receive climbing fiber collaterals from MAO and DAO. The DCN send reciprocating GABAergic projections back to the IO subnuclei. These connections are highly organized with somatotopic precision. 56, 67

**Climbing fibers are required for tremor expression.** The destruction of IO by systemic 3-acetylpyridine injection eliminates the tremor response. 66 If the cerebellar peduncles are cut to sever climbing fibers, the MAO and DAO still show bursting and increased glucose utilization by harmaline, whereas Purkinje cell and fastigial nucleus bursting is abolished, and metabolic activation of other medulla structures fails to occur. 66, 68 The importance of climbing fibers is also illustrated in genetically dystonic rats, which do not show normal climbing fiber-induced complex spike responses. 69 On harmaline administration, IO neurons but not Purkinje cells, fire rhythmically, and tremor does not occur. 60, 70

**Are Purkinje cells required for tremor?** Cooling of the cerebellar cortex does not abolish harmaline-induced motoneuron firing, suggesting that the olivo–DCN loop may be sufficient for tremor. 61 Mice with Purkinje cell degeneration (pcd) still manifest harmaline tremor despite the complete absence of Purkinje cells, although the tremor is of lower frequency and amplitude than controls. Lurcher mice also have no Purkinje neurons, but mount no harmaline tremor. The difference between these two strains of mice is that pcd mice have intact climbing fibers capable of contacting DCN neurons, whereas lurcher mice appear not to. 71

**What is the role of DCN in tremor?** DCN neurons, as the sole output of the cerebellum, are required for the expression of harmaline tremor. On the other hand, lesions of the dentate nucleus or DCN outflow pathways are well known to induce action tremor in humans, 72 and lesions or inhibitory injections of the interpositus nucleus or combined lesions of interpositus and dentate nucleus can induce action tremor in monkeys. 73–75 Thus DCN paradoxically can express and suppress tremor. On adding harmaline to a guinea pig cerebellum-brainstem in situ preparation, one group of DCN neurons responds with an excitatory post-synaptic potential, an inhibitory post-synaptic potential (IPSP), then a rebound discharge, whereas another group responds with an initial IPSP followed by a rebound discharge. These responses have been interpreted to indicate that harmaline induces phasic rhythmic activity in excitatory DCN output neurons, thereby expressing tremor, and in inhibitory nucleo-olivary neurons, thereby modulating rhythmicity and synchronicity. 76
Are the brainstem and spinal cord sufficient for harmaline tremor? Cooling of the motor cerebral cortex and lesions of the ventrolateral thalamus or globus pallidus reportedly do not affect harmaline tremor in intact monkeys.77,78 Not even intercollicular decerebration abolishes tremor in cats or monkeys.78,79 These observations suggest that the brainstem and spinal cord are sufficient to express harmaline tremor, even in primates. On the other hand, high-frequency stimulation stimulating deep brain stimulation (DBS) of the ventrolateral thalamus, and intrathalamic infusion of muscimol or an adenosine A1 receptor agonist suppress harmaline tremor in mice,80 indicating a potential role of the thalamus in modulating harmaline tremor.

Summary. Harmaline induces rhythmic bursting in accessory IO neurons that then recruits medial regions of cerebellar cortex and DGN. The end result is rhythmic activation of the spinal gamma and alpha motoneurons and tremor.

Proposed mechanisms of harmaline tremor

Here we consider the question how harmaline acts at the cellular level to induce tremor.

Serotonin. Initial ligand binding studies indicated that harmaline does not bind significantly to 5-hydroxytryptamine (HT)1a-4 or 5-HT1 receptors (Ka>100 μM).81 Subsequently harmaline was found to have affinity to the 5-HT2a (Ka=7.3, 42.5 μM) and 5-HT2c (Ka=9.4 μM) receptors,82,83 comparable to the cerebellar harmaline level of 18.2 μM after 15 mg/kg in mice.84 Acting through 5-HT2a receptors, intra-IO 5-HT injection increases IO neuronal firing rates and improves coherence, while increasing intra-band Purkinje cell synchrony, similar to harmaline, but harmaline’s action is not blocked by a 5-HT2a antagonist.85

NMDA receptor channel. Harmaline competitively displaces tritiated MK801 (dizocilpine) from the NMDA receptor in rabbit IO fractions (IC50 60 μM),86 leading to the suggestion that harmaline induces tremor by acting as an NMDA receptor inverse agonist. However this action would produce depolarization, whereas harmaline hyperpolarizes IO neurons.

Benzodiazepine receptor. Harmaline displaces tritiated flunitrazepam from brain tissue only at high IC50 concentrations: 126–600 μM.84,87 The benzodiazepine antagonists flumazenil and CGS8216 do not affect harmaline tremor in mice.88 Moreover, binding of H-flunitrazepam in IO of adult rodents is very sparse.89 Harmaline is thus not likely to induce tremor via benzodiazepine receptors.

Sodium and high-voltage calcium conductances. Harmaline does not significantly displace ligands at adrenergic, dopamine, opiate, muscarinic, nicotinic, GABA receptors or the chloride channel. An affinity for the voltage-gated sodium channel, (Ka=13.9 μM), suggested this as a potential mechanism of tremor.81 However, very high levels of harmaline are needed to affect the action potential (>0.5 mM).90 At 100 μM, harmaline inhibits sodium conductance by 23% in dorsal root ganglia neurons. High-voltage calcium channels (L- and N-type) are more sensitive, with an IC50 by harmaline of 100 μM. However harmaline, which is less tremorigenic, is more potent (IC50=76 μM),91 thus this channel is not likely to mediate tremor.

The Cav3.1 T-type calcium channel. IO slices from Cav3.1-null mice fail to show STOs or low-threshold calcium spikes. Harmaline fails to produce rhythmic firing in IO slices from Cav3.1 null mice.64 Park et al.64 studied harmaline effects on Cav3.1 currents in vitro and found a complex set of actions that in combination leads to enhanced rebound spikes. They postulate that harmaline engenders tremor by effects on the Cav3.1 channel.64 Effects on Cav3.2 or Cav3.3 channels were not studied.

Other actions. Harmaline inhibits sodium-dependent transport of substances into various tissues, such as choline into striatal synaptosomes (Ka=36 μM),92 and gamma-hydroxybutyrate into whole-brain synaptosomes (Ka=94 μM).83 Harmaline is a potent inhibitor of MAO-A, with IC50 values as low as 4–8 nM. Activity against MAO-B is negligible.94 Harmaline inhibits synaptosomal GABA uptake (IC50 47 μM)95 and dopamine uptake (IC50=8.1 μM),96 and increases dopamine release from striatal slices at 6 μM.94 Low doses enhance levodopa-induced stereotypy in mice.97 These observations are compatible with reports that Parkinson’s motor symptoms are ameliorated by extracts of B. caapi.94 Harmaline also potently inhibits cerebral histamine N-methyltransferase (IC50=4.4 μM), which may raise histamine levels,98 and displaces tritiated tryptamine is brain tissue (IC50=25 μM).99 Harmaline potently binds the imidazoline 2B receptor (Ka=177 nM).100

Summary. Several potential mechanisms by which harmaline could produce tremor have been investigated. At present the most likely mechanism appears to be modulation of T-type calcium channels. It is not clear whether this action is restricted to Cav3.1 channels or also involves Cav3.2 and Cav3.3. Harmaline is a potent inhibitor of MAO-A, and has significant effects on dopamine and histamine processing.

The pharmacology of harmaline tremor

Serotonin (5-HT). Serotonergic fiber innervation in IO is highest in caudal MAO and caudolateral DAO, correlating with high sensitivity to harmaline-induced rhythmicity.101,102 Lesions of 5-HT fibers to the IO, or of the medial and dorsal raphe nuclei, reduce the harmaline tremor response.101,103 The genetically epilepsy-prone rat (GEPR) has reduced serotonergic IO innervation, and manifests poor harmaline tremor.104 Harmine tremor is exacerbated by the 5-HT precursor 5-hydroxytryptophan,103 an effect reduced by raphe lesions.103 Conversely, the broad-spectrum 5-HT antagonist methysergide and the 5-HT synthesis inhibitor para-chlorophenylalanine reduce harmaline tremor.105,106 The serotonin uptake inhibitor citalopram (10–40 mg/kg) enhances harmaline tremor in rats,107 as does imipramine.106

Norepinephrine. When norepinephrine is added to guinea pig brainstem slices, harmaline-induced rhythmic IO oscillations ceases.37
Systemic injection of the norepinephrine precursor L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS, 50–200 mg/kg) suppresses harmaline tremor in rats. Intraventricular L-threo-DOPS also suppresses harmaline tremor, as does electrical stimulation of locus ceruleus. In contrast, the tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine, 200 mg/kg; 6-hydroxydopamine injections that reduce cerebellar norepinephrine; and locus ceruleus destruction each exacerbate harmaline tremor.

Beta-adrenergic blockers such as propranolol suppress harmaline and harmine tremor in rodents. Selective beta- and beta-adrenergic antagonists can each suppress harmaline tremor in rats, but beta-blockade may be more effective. Although propranolol may act in part peripherally, it also acts directly by antagonizing the electrophysiological effects of harmaline on IO neurons in brainstem slices. In contrast, the alpha-adrenergic antagonist phenoxybenzamine does not suppress harmine tremor, and is ineffective for ET.

Glutamate. Intracisternal 2-aminophosphonovalerate (2-APV), an NMDA receptor antagonist, suppresses harmaline tremor in mice. Similarly the competitive NMDA antagonist d-CPPene suppresses harmaline tremor in mice and rats. The non-competitive NMDA antagonist dizocilpine (MK-801) potently suppresses harmaline tremor in mice and rabbits, as does phencyclidine in mice. Memantine has only a weak antitremor effect in rats, comparable to a weak or non-existent effect on ET. However, memantine confers striking protection against harmaline-induced cell loss in the cerebellum and IO.

The AMPA receptor antagonist RPR117824 suppresses harmaline tremor, as does NBQX disodium salt. The mGluR1 antagonist JNJ 16259685-a strongly enhances harmaline tremor in rats, suggesting an agonist at this receptor should suppress tremor. In contrast, the mGluR5 receptor antagonist 6-methyl-2-[phenylethynyl]pyridine (MPEP) has no effect in mice. The GABA A receptor agonist muscimol also suppresses harmaline tremor in mice. The GABA B receptor agonist baclofen, 2.5–10 mg/kg, dose-dependently suppress harmaline tremor in rats, and reduces harmaline tremor in alcohol-withdrawing rats. However Paterson et al. did not find tremor suppression by baclofen in mice.

Dopamine (DA). Harmine tremor is reduced by levodopa and by the agonists apomorphine and piribedil in rats and mice. Similarly the dopamine uptake inhibitor GBR12909 reduces tremor. Apomorphine is a D 1/D 2 agonist. Tremor is not reduced by the D 1 agonist SKF82958, but is by the D 2/D 3 agonist quinpirole.

Alcohol. Suppression of harmaline tremor by ethanol has been well replicated, but the site of action and mechanism remain unclear. Ethanol reduces harmaline tremor in mice at low doses that do not suppress harmaline-induced cerebellar cyclic GMP elevations. This observed dissociation between ethanol’s climbing fiber-mediated and behavioral effects raised the possibility of an extra-olivary localization of the antitremor action. In rats anesthetized with agents other than urethane, or immobilized and given local anesthesia, ethanol increases IO firing rates. A moderate ethanol dose (1 g/kg) increases vermal Purkinje cell complex spike rhythmicity and synchrony in ketamine-anesthetized rats, and by inference IO ensemble rhythmicity and synchrony. Moreover ethanol fails to affect the rhythmicity of harmaline-induced complex spike activity. These observations suggest that alcohol does not suppress but instead increases IO firing with potentially excitotoxic effects. This inference is supported by the finding that although ethanol, 1.5 g/kg, effectively suppresses tremor in rats, histology 24 hours later reveals that ethanol-treated rats display an exacerbation of the harmaline-associated vermal and paravermal Purkinje and granule cell loss, and more IO neuronal loss. Conceivably alcohol’s antitremor efficacy may lure ET patients to alcohol-exacerbated cerebellar damage, to which they may be more vulnerable.

Antiepileptic drugs. De Ryck et al. found antitremor effects for primidone, clonazepam, gabapentin, and carbamazepine. Whereas levetiracetam had minimal effect on tremor, the derivative brivaracetam was effective. Similarly, Paterson et al. found that primidone, gabapentin, and carbamazepine suppress harmaline tremor in mice, but also reported that valproate does as well. Zonisamide suppresses harmaline tremor in mice, with 50 mg/kg more effective than 5 mg/kg. Zonisamide has shown efficacy for ET. Lacosamide, 0.3–30 mg/kg, suppresses harmaline tremor in rats; however, a clinical trial did not show efficacy for ET. Similarly, carisbamate suppressed harmaline tremor in preclinical testing, but demonstrated no antitremor efficacy in an ET trial.

Gap junction blockers. Contrary to expectation, Cx36-null mice or mice with IO transduction of inactive mutant Cx36 mount a vigorous tremor response to harmaline. On the other hand, harmaline tremor is suppressed by the broad-spectrum gap junction blocker carbenoxolone and by more specific mefloquine. It may be conjectured that other gap junctions also play a role in harmaline tremor, such as connexin 57. More research on this topic is warranted.

T-type calcium channels. Isomers of octanol suppress harmaline tremor in the rat. Because octanol blocks T-type calcium channels it was predicted that antagonists of these channels could be effective for tremor. However, octanol exerts multiple actions. We showed that each of five drugs that block T-type calcium channels suppress tremor in the harmaline model and in the GABA A z1-null genetic mouse tremor model. The best agent appeared to be NNC55-0396. Of the three subtypes of T-type calcium channels, Cav3.1 is expressed in IO, Purkinje cells and some DCN neurons. Park et al. reported that Cav3.1-null mice generated in the laboratory of HS Shin are impaired in manifesting harmaline tremor. This was demonstrated with a low harmaline dose that in wild-type mice induced tremor for only 15 minutes. Tremor was greatly reduced in Cav3.1-null mice, but...
Harmaline Tremor Handforth A

Adenosine. Harmaline tremor is enhanced by the adenosine receptor agonist caffeine, 50–150 mg/kg, in rats,141 and by the A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 4 mg/kg, in mice.80 Intrathalamic infusion of adenosine or the A1 receptor agonist 2-chloro-N6-cyclopentyladenosine reduces harmaline tremor. Infusion of DPCPX or the use of A1 receptor null mice reduces the threshold for DBS-induced involuntary movements (related to glutamate release), so that tremor cannot be suppressed by DBS. Thalamic DBS is suggested to cause local adenosine release that limits glutamate effects, enabling tremor to be suppressed at current levels below those associated with involuntary movements.

Other drugs. Anticholinergics do not reduce harmine tremor in rodents.113 Harmaline tremor is suppressed by systemic lidocaine (12.5–50 mg/kg);142 dantrolene, 10 mg/kg;124 lithium, 2 mEq,116 in mice; and 16-methyl-prostaglandin E2 (PGE2), 25–50 μg/kg, in cats.143 Conversely, harmine tremor is enhanced by cyclosporin, 25–50 mg/kg, in mice.144 MK-0249, a histamine-3 receptor inverse agonist, suppresses harmaline tremor, but does not suppress ET tremor.145

Summary. Knowledge of the physiology and the basic circuit of harmaline tremor (Figure 3) suggests that drugs affecting specific ion conductances, such as the T-type calcium channel, gap junctions, glutamate, and GABA receptors should affect tremor; notions that have received support. In addition, the tremorigenic circuit is susceptible to influence by various neurotransmitter systems, including norepinephrine, 5-HT and DA. Further research is likely to reveal more neuromodulators of tremor.

Harmaline tremor as a preclinical model of ET

Comparison with ET. Harmaline-induced tremor has been suggested as useful for preclinical screening of potential ET therapies. ET and the harmaline animal model differ in a number of respects, however, and the harmaline model possesses limitations.

Harmaline tremor is an acute state induced pharmacologically, following which animals are resistant to further doses. In contrast, ET develops gradually, and is chronic, without remission. Based on associations of lower risk for ET with smoking and a Mediterranean diet,13,146 and findings of Purkinje cell loss with cerebellar cortical gliosis or locus ceruleus depletion and/or Lewy bodies, it appears likely that at least in some cases ET is a neurodegenerative disorder.147 Harmaline acts on the IO to produce tremor. In ET, the role of IO is less certain. In ET subjects, eye-blink conditioning, which depends on the olivocerebellar pathway, is impaired.148 One imaging study found increased glucose utilization in the IO region in ET,149 but another study found no change in IO blood flow.150 Cerebellar cortical hypermetabolism, known to depend in the harmaline model on climbing fiber activation, also occurs in ET.149–151 Interestingly, alcohol administration suppresses cerebellar hypermetabolism in ET subjects, and increases IO blood flow, which does not happen in controls, suggesting that IO physiology differs in ET.151 Each pharmacotherapy suppresses tremor in only a fraction of ET patients. Given ET’s heterogeneity, it is uncertain to what extent harmaline or any other animal model can offer predictive success.

Another caveat in comparing drug efficacy for harmaline vs. ET is that, based on published reports, it is difficult to assess to what extent suppression of harmaline tremor is a non-specific effect of sedation or reductions in motor activity. Potential approaches are to employ tremor measures that are insensitive to locomotor activity levels, and to select doses shown in independent behavioral tests not to affect motor activity.

How accurate is the harmaline model in predicting efficacy for ET? An initial prediction was encouraging. Sinton et al.152 reported in 1989 that isomers of octanol suppress harmaline tremor in the rat, subsequently replicated in mice.153 Early-stage clinical trials later demonstrated that 1-octanol reduces tremor in ET.152 In humans,
1-octanol is rapidly converted to octanoic acid, which may be the active antitremor agent.\textsuperscript{153}

Citalopram, imipramine and caffeine worsen both harmaline\textsuperscript{107,143} and ET tremor (Table 1). We do not know of any agent that fails to suppress harmaline tremor yet is effective for ET. Phenoxybenzamine, levetiracetam, and anticholinergics do not suppress harmaline tremor, and do not usually suppress tremor in ET.

Of 16 agents reported to suppress harmaline tremor, including weakly effective memantine, seven fail to suppress ET tremor, including several anti-epileptic drugs,\textsuperscript{133,134,154} levodopa and dopamine agonists,\textsuperscript{103}

### Table 1. Comparison of Harmaline Rodent Tremor Model and Essential Tremor

| Feature                          | Harmaline Tremor | Essential Tremor |
|----------------------------------|------------------|-----------------|
| **Clinical**                     |                  |                 |
| Action tremor                    | Yes              | Yes             |
| Time course                      | Acute            | Chronic         |
| Inducing agent                   | Pharmacologic    | Probably neurodegenerative |
| Role of inferior olive           | Definite         | Uncertain       |
| Cerebellar hypermetabolism      | Yes              | Yes             |
| **Response to drugs**            |                  |                 |
| Caffeine                         | Worsens          | Worsens in some |
| Citalopram, imipramine          | Worsens          | Worsens in some |
| Phenoxylbenzamine                | Does not suppress| Does not suppress|
| Anticholinergics                 | Do not suppress  | Do not suppress  |
| Levetiracetam                    | Does not suppress| Does not suppress|
| Primidone                        | Suppresses       | Suppresses in some |
| Clonazepam, diazepam             | Suppresses       | Suppresses in some |
| Gabapentin                       | Suppresses       | Suppresses in some |
| Carbamazepine                    | Suppresses       | Does not suppress |
| Valproate                        | Suppresses       | Does not suppress/worsens |
| Zonisamide                       | Suppresses       | Suppresses in some |
| Lacosamide                       | Suppresses       | Does not suppress |
| Carisbamate                      | Suppresses       | Does not suppress |
| Propranolol                      | Suppresses       | Suppresses in some |
| L-dopa, DA agonists              | Suppresses       | Do not suppress  |
| Ethanol                          | Suppresses       | Suppresses in some |
| Gamma-hydroxybutyrate            | Suppresses       | Suppresses in some |
| Lithium                          | Suppresses       | Does not suppress/worsens |
| 1-Octanol                        | Suppresses       | Suppresses in some |
| Memantine                        | Weakly suppresses| Weak or no suppression |
| MK-0249                          | Suppresses       | Does not suppress |

Handforth A Harmaline Tremor

Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org

The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services
lithium, and MK-0249. Matches between positive results in the harmaline model and efficacy in ET trials occurred in 9 out of 16 agents or a 56% concordance rate, and include propranolol, several antiepileptic drugs, alcohol, memantine, and gamma-hydroxybutyrate.

Because some of these agents were tested in the model after having been found effective in ET, the true predictive success rate for the model may be lower than 56%.

Summary. As is often the case with neurological disease models, the harmaline model is prone to false positives. Because the harmaline state is poorly compatible with sensitive tests of drug intoxication, independent tests of behavioral tolerability in non-harmaline control subjects may be appropriate.

Conclusion

Like ET, harmaline induces an action tremor that involves cerebellar circuitry, and responds to drugs that suppress clinical tremor. Unlike ET, harmaline tremor is acute and temporary. Harmaline converts IO STOs to rhythmic burst firing that is propagated through the cerebellum, then ultimately activates spinal motoneurons to express tremor. The minimum cerebellar circuit required includes the IO, climbing fibers and DCN. Pharmacologic studies indicate that harmaline tremor severity is influenced by several ghtamate receptors, GABA A and B receptors, serotonin receptors, norepinephrine receptors, dopamine receptors, gap junctions, T-type calcium channels, alcohol, and antiepileptic drugs. Of drugs that suppress harmaline tremor, approximately half suppress ET tremor.

Acknowledgments

We are grateful to Elan Louis, MD, for constructive comments and to Hovsep Kosoyan, PhD, for assistance with figures.

References

1. Guan Y, Louis ED, Zheng W. Toxicokinetics of tremorogenic natural products, harmine and harmine, in male Sprague-Dawley rats. J Toxicol Environ Health A 2001;64:645–660, doi: http://dx.doi.org/10.1080/152873901753246241.

2. Callaway JC, Airaksinen MM, Salmela KS, Salaspuro M. Formation of tetrahydroharmann (1-methyl-1,2,3,4-tetrahydro-beta-carboline) by Helicobacter pylori in the presence of ethanol and tryptamine. J Neurochem 1998;70:727–735, doi: http://dx.doi.org/10.1046/j.1471-4159.1998.7002072.x.

3. Raaymakers J, Kokken A, Van den Bogaert B, Gonzalez R, Ferrante S. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated ς-carboline and isouquinoline alkaloids, by human cytochrome P450 2D6. Toxicol Appl Pharmacol 2002;162:387–398, doi: http://dx.doi.org/10.1016/j.taap.2006.06.003.

4. McCann SJ, Pond SM, James KM, Le Couteur DG. The association between polymorphisms in the cytochrome P450 2D6 gene and Parkinson’s disease: a case-control study and meta-analysis. J Neurol Sci 1997;153:50–53, doi: http://dx.doi.org/10.1016/S0022-510X(97)00179-2.

5. Miksys S, Rizzo V, Mash DC, Tyndale RF. Nicotine induces brain CYP enzymes: relevance to cigarette smoking and risk of incident essential tremor. J Pharmacol Exp Ther 2003;305:315–322, doi: http://dx.doi.org/10.1124/jpet.102.047050.

6. Miksys S, Rao Y, Hoffmann E, Mash DG, Tyndale RF. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 2002;82:1376–1387, doi: http://dx.doi.org/10.1046/j.1471-4159.2002.01069.x.

7. Miksys S, Tyndale RF. Nicotine induces brain CYP enzymes: relevance to Parkinson’s disease. J Neural Transm Suppl 2006;70:177–180, doi: http://dx.doi.org/10.1007/978-3-211-45295-0_28.

8. Gearhart DA, Neafsey EJ, Collins MA. Phenylenolamine N-methyltransferase has ς-carboline 2’-N-methyltransferase activity: hypothetical relevance to Parkinson’s disease. Neurochem Int 2002;40:611–620, doi: http://dx.doi.org/10.1016/S0197-0186(01)00115-2.

9. Herraiz T, Guilleñ H, Galisteo J. N-methyltetrahydro-D-carboline analogs of 1-methyl-D-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin are oxidized to neurotoxic ς-carbolinium cations by heme peroxidases. Biochem Biophys Res Commun 2007;356:118–123, doi: http://dx.doi.org/10.1016/j.bbrc.2007.02.089.

10. Miksys S, Gonda T, Sawada H et al. Endogenously occurring ς-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson’s disease. J Neurochem 1998;70:727–735, doi: http://dx.doi.org/10.1046/j.1471-4159.1998.7002072.x.

11. Miksys S, Gonda T, Sawada H et al. Endogenously occurring ς-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson’s disease. J Neurochem 1998;70:727–735, doi: http://dx.doi.org/10.1046/j.1471-4159.1998.7002072.x.

12. Miksys S, Gonda T, Sawada H et al. Endogenously occurring ς-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson’s disease. J Neurochem 1998;70:727–735, doi: http://dx.doi.org/10.1046/j.1471-4159.1998.7002072.x.
20. Pennes HH, Hoch PH. Psychotomimetics, clinical and theoretical considerations: harmine, Win-2299 and nalline. Am J Psychiatry 1957;113:887–892.
21. Ahmed A, Taylor NR. The analysis of drug-induced tremor in mice. Br J Pharmacol Chemother 1959;14:350–354.
22. de Montigny C, Lamarre Y. Rhythmic activity induced by harmaline in the olivo-cerebello-bulbar system of the cat. Brain Res 1973;53:81–95, doi: http://dx.doi.org/10.1016/0006-8993(73)90768-3.
23. Poirier LJ, Sourkes TL, Bouvier G, Boucher R, Carabin S. Striatal amines, experimental tremor and the effect of harmaline in the monkey. Brain 1966;89:57–52, doi: http://dx.doi.org/10.1093/brain/89.1.37.
24. Miwa H. Rodent models of tremor. Cerebellum 2007;6:66–72, doi: http://dx.doi.org/10.1080/14734290601016080.
25. Miwa H, Hama K, Kajimoto Y, Kondo T. Effects of zonisamide on experimental tremors in rats. Parkinsonism Relat Disord 2008;14:33–36, doi: http://dx.doi.org/10.1016/j.parkreldis.2007.05.008.
26. Wang G, Fowler SC. Concurrent quantification of tremor and depression of locomotor activity induced in rats by harmaline and physostigmine. Psychopharmacology (Berl) 2001;158:273–280, doi: http://dx.doi.org/10.1007/s002130100882.
27. de Souza da Fonseca A, Pereira FR, Santos R. Validation of a new computerized system for recording and analysing drug-induced tremor in rats. J Pharmcol Toxicol Methods 2001;46:137–143, doi: http://dx.doi.org/10.1016/S1056-8719(02)00169-7.
28. Martin FC, Thu Le A, Handforth A. Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications. J Physiol 2001;543:V255–V275.
29. Stanford J, Fowler SC. At low doses, harmaline increases forelimb tremor in the rat. Neuroscience 1999;255:275–286, doi: http://dx.doi.org/10.1016/S0306-4522(98)00772-7.
30. Lutes J, Lorden JF, Beales M, Oltmans GA. Tolerance to the tremorogenic effects of harmaline: evidence for altered olivo-cerebellar function. Neuropharmacology 1988;27:849–855, doi: http://dx.doi.org/10.1016/S0028-3908(88)90102-5.
31. Lorden JF, Stratton SE, Mays LE, Oltmans GA. Purkinje cell activity in rats following chronic treatment with harmaline. Neuroscience 1988;27:465–472, doi: http://dx.doi.org/10.1016/0306-4522(88)90281-3.
32. Stratton SE, Lorden JF. Effect of harmaline on cells of the inferior olive in the absence of tremor: differential response of genetically dystonic and harmaline-tolerant rats. Neuroscience 1991;41:543–549, doi: http://dx.doi.org/10.1016/0306-4522(91)90347-Q.
33. O’Hearn E, Moliver ME. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 1993;55:303–310, doi: http://dx.doi.org/10.1016/0306-4522(93)90500-F.
34. Miwa H, Kubo T, Suzuki A, Kihara T, Kondo T. A species-specific difference in the effects of harmaline on the rodent olivo-cerebellar system. Brain Res 2006;1066:94–101, doi: http://dx.doi.org/10.1016/j.brainres.2005.11.036.
35. Llinás R, Yarom Y. Electrophysiology of mammalian inferior olivary neurones in vitro. Different types of voltage-dependent ionic conductances. J Physiol 1981;315:549–567.
36. Llinás R, Yarom Y. Properties and distribution of ionic conductances generating electrophoresponsiveness of mammalian inferior olivary neurones in vitro. J Physiol 1981;315:569–584.
37. Llinás R, Yarom Y. Oscillatory properties of guinea-pig inferior olivary neurones and their pharmacological modulation: an in vitro study. J Physiol 1986;376:163–182.
38. Lang EF, Sugihara I, Llinás R. Differential roles of amamin- and charybdotoxin-sensitive K+ conductances in the generation of inferior olive rhythmity in vivo. J Neurol 1997;282:253–2538.
39. Placantonakis DG, Schwarz C, Welsh JP. Serotonin suppresses subthreshold and suprathreshold oscillatory activity of rat inferior olivary neurones in vitro. J Physiol 2000;524:333–351, doi: http://dx.doi.org/10.1111/j.1469-7793.2000.00833.x.
40. Placantonakis D, Welsh J. Two distinct oscillatory states determined by the NMDA receptor in rat inferior olive. J Physiol 2001;534:123–140, doi: http://dx.doi.org/10.1111/j.1469-7793.2001.t01-1-00123.x.
41. Degen J, Meier C, Van Der Giessen RS et al. Expression pattern of lacZ reporter gene representing connexin36 in transgenic mice. J Comp Neurol 2004; 473:511–525, doi: http://dx.doi.org/10.1002/cne.20085.
42. Leznik E, Makarenko V, Llinás R. Electrotonically mediated oscillatory patterns in neuronal ensembles: an in vitro voltage-dependent dye-imaging study in the inferior olive. J Neurosci 2002;22:2804–2815.
43. Sotelo C, Llinás R, Baker R. Structural study of inferior olivary nucleus of the cat: morphological correlates of electrotonic coupling. J Neurophysiol 1974; 37:541–559.
44. Leznik E, Llinás R. Role of gap junctions in synchronized neuronal oscillations in the inferior olive. J Neurophysiol 2005;94:2447–2456, doi: http://dx.doi.org/10.1152/jn.00353.2005.
45. De Zeeuw CI, Van Alphen AM, Hawkins RK, Ruigrok TJ. Climbing fibre collaterals contact neurons in the cerebellar nuclei that provide a GABAergic feedback to the inferior olive. Neuroscience 1997;80:981–986, doi: http://dx.doi.org/10.1016/S0306-4522(97)00249-2.
46. Sasaki K, Bower JM, Llinás R. Multiple purkinje cell recording in rodent cerebellar cortex. Eur J Neurosci 1989;1:572–586, doi: http://dx.doi.org/10.1111/j.1460-9568.1989.tb00364.x.
47. Lang EF, Sugihara I, Llinás R. GABAergic modulation of complex spike activity by the cerebellar nucleo-olivary pathway in rat. J Neurophysiol 1996;76: 255–275.
48. Lang EF. GABAergic and glutamatergic modulation of spontaneous and motor-cortex-evoked complex spike activity. J Neurophysiol 2002;87:1993–2008.
49. Welsh JP, Lang EF, Sugihara I, Llinás R. Dynamic organization of motor control within the olivocerebellar system. Nature 1995;374:543–547, doi: http://dx.doi.org/10.1038/374453a0.
50. Van Der Giessen RS, Maxeiner S, French PJ, Willecke K, De Zeeuw CI. Spatiotemporal distribution of Connexin36 in the olivocerebellar system. J Comp Neurol 2006;495:173–184, doi: http://dx.doi.org/10.1002/cne.20873.
51. Long MA, Deans MR, Paul DL, Connors BW. Rhythmicity without synchrony in the electrically uncoupled inferior olive. J Neurol 2002;22:10890–10905.
52. Placantonakis DG, Bukovsky AA, Zeng XH, Kiern HP, Welsh JP. Fundamental role of inferior olive connexin 36 in muscle coherence during
Harmaline Tremor

Handforth A

Proc Natl Acad Sci USA 2004;101:7164–7169, doi: http://dx.doi.org/10.1073/pnas.040032101.

53. Placantonakis DG, Bukovsky AA, Aicher SA, Kiern HP, Welsh JP. Continuous electrical oscillations emerge from a coupled network: a study of the inferior olive using lentiviral knockdown of connexin36. J Neurosci 2006;26:5008–5016, doi: http://dx.doi.org/10.1523/JNEUROSCI.046-06.2006.

54. Marshall SP, van der Giesen RS, de Zeeuw CI, Lang PJ. Altered olivocerebellar activity patterns in the connexin36 knockout mouse. Cerebellum 2007;28:1–13.

55. Blenkenop TA, Lang PJ. Block of inferior olive gap junctional coupling decreases Purkinje cell complex spike synchrony and rhythmicity. J Neurosci 2006;26:1739–1748, doi: http://dx.doi.org/10.1523/JNEUROSCI.3677-05.2006.

56. Teune TM, van der Burg J, de Zeeuw CI, Voogel J, Ruigrok TJ. Single Purkinje cell can innervate multiple classes of projection neurons in the cerebellar nuclei of the rat: a light microscopic and ultrastructural triple-tracer study in the rat. J Comp Neurol 1998;392:164–178, doi: http://dx.doi.org/10.1002/(SICI)1096-9886(19980309)392:2<164::AID-CNE2>3.0.CO;2-0.

57. Molineux ML, McKory JE, McKay BE et al. Specific T-type calcium channel isoforms are associated with distinct burst phenotypes in deep cerebellar nuclear neurons. Proc Natl Acad Sci USA 2006;103:5555–5560, doi: http://dx.doi.org/10.1073/pnas.0601261103.

58. Uusisaari M, Ohtaa K, Knöpfel T. Morphological and electrophysiological properties of GABAergic and non-GABAergic cells in the deep cerebellar nuclei. J Neurophysiol 2007;97:901–911, doi: http://dx.doi.org/10.1152/jn.01129.2006.

59. De Montigny C, Lamarre Y. Effects produced by local applications of harmaline in the inferior olive. Can J Physiol Pharmacol 1975;53:845–849, doi: http://dx.doi.org/10.1139/y75-116.

60. Batini C, Bernard JF, Buisseret-Delmas C, Conrath-Verrier M, Horcholle-Bossavit G. Harmaline-induced tremor. II. Unit activity correlation in the interposito-rubral and oculomotor systems of cat. Exp Brain Res 1984;57:128–137, doi: http://dx.doi.org/10.1007/BF00231139.

61. Linias R, Volkland RA. The olivo-cerebellar system: functional properties as revealed by harmaline-induced tremor. Exp Brain Res 1973;16:89–97, doi: http://dx.doi.org/10.1007/BF00235703.

62. Batini C, Bernard JF, Buisseret-Delmas C, Conrath-Verrier M, Horcholle-Bossavit G. Harmaline-induced tremor. II. Regional metabolic activity as revealed by [14C]-2-deoxyglucose in the inferior olive. J Neurocytol 2003;32:330–334, doi: http://dx.doi.org/10.1016/j.jneurosci.2003.09.015.

63. Battista AF, Nakatani S, Goldstein M, Anagnoste B. Effect of harmaline in monkeys with central nervous system lesions. Exp Neurol 1970;28:513–524, doi: http://dx.doi.org/10.1016/0014-4886(70)90189-5.

64. Park YG, Park HY, Lee CJ et al. CaV3.1 is a tremor rhythm pacemaker in the inferior olive. Proc Natl Acad Sci USA 2010;107:10731–10736, doi: http://dx.doi.org/10.1073/pnas.1002995107.

65. Bernard JF, Buisseret-Delmas C, Comptoin C, Laplante S. Harmaline induced tremor. III. A combined simple units, horseradish peroxidase, and 2-deoxyglucose study of the olivocerebellar system in the rat. Exp Brain Res 1984;57:128–137, doi: http://dx.doi.org/10.1007/BF00231139.
radioligand binding studies. *Brain Res* 1992;571:242–247, doi: http://dx.doi.org/10.1016/0006-8993(92)90661-R.

82. Heldsley S, Fiorella D, Rabin RA, Winter JC. Behavioral and biochemical evidence for a nonessential 5-HT2A component of the ibogaine-induced discriminative stimulus. *Pharmacol Biochem Behav* 1998;59:419–425, doi: http://dx.doi.org/10.1016/S0091-3057(97)00451-6.

83. Grella B, Dukat M, Young R et al. Investigation of hallucinogenic and related β-carbolines. *Drug Alcohol Depend* 1998;50:99–107, doi: http://dx.doi.org/10.1016/S0376-8716(97)00163-4.

84. Robertson HA. Harmaline-induced tremor: the benzodiazepine receptor as a site of action. *Eur J Pharmacol* 1980;67:129–132, doi: http://dx.doi.org/10.1016/0014-2990(80)90020-5.

85. Sugihara I, Lang EJ, Llinás R. Serotonin modulation of inferior olivary oscillations and synchronicity: a multiple-electrode study in the rat cerebellum. *Eur J Neurosci* 1995;7:521–534, doi: http://dx.doi.org/10.1111/j.1460-9568.1995.tb00657.x.

86. Du W, Aloyo VJ, Harvey JA. Harmaline competitively inhibits [3H]MK-801 binding to the NMDA receptor in rabbit brain. *Brain Res* 1997;770:245–246, doi: http://dx.doi.org/10.1016/0006-2952(97)00060-9.

87. Mousah H, Jaenpin P, Lesne M. Interaction of carbolines and some GABA receptor ligands with the GABA and the benzodiazepine receptors. *J Pharmacol* 1986;178:56–60.

88. Schweri M, Caim M, Cook J, Paul S, Skolnick P. Blockade of 3-carbomethoxy-β-carboline-induced seizures by diazepam and the benzodiazepine antagonists, Ro 15-1788 and CGS8216. *Pharmacol Biochem Behav* 1982;17:457–460, doi: http://dx.doi.org/10.1016/0091-3057(92)90304-5.

89. Frostholm A, Evans JE, Cummings SL, Rotter A. Harmaline-induced changes in gamma aminobutyric acidA receptor subunit mRNA expression in murine olivocerebellar nuclei. *Brain Res Mol Brain Res* 2000;85:200–208, doi: http://dx.doi.org/10.1016/S0304-3940(00)00529-X.

90. Ishida H, Sasa M, Takaori S, Ishida H. Effects of harmaline on membrane excitability and ATPase activity of the crayfish giant axon. *Jpn J Pharmacol* 1981;31:801–807, doi: http://dx.doi.org/10.1254/jpp.31.801.

91. Spletstoesser F, Bonnet U, Wiemann M, Bingmann D, Büsselberg D. Modulation of voltage-gated channel currents by harmaline and harmamine. *Br J Pharmacol* 2005;144:52–58, doi: http://dx.doi.org/10.1038/sj.bjp.0706024.

92. Smart L. Competitive inhibition of sodium-dependent high affinity choline uptake by harmala alkaloids. *Eur J Pharmacol* 1981;75:265–269, doi: http://dx.doi.org/10.1016/0014-2999(81)90533-7.

93. McCormick SJ, Tummler G. Inhibitors of synaptosomal gamma-hydroxybutyrate transport. *Pharmacology* 1980;57:124–131, doi: http://dx.doi.org/10.1159/000283543.

94. Schwarz MJ, Houghton PJ, Rose S, Jenner P, Lees AD. Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism. *Pharmacol Biochem Behav* 2003;75:627–633, doi: http://dx.doi.org/10.1016/S0091-3057(03)0129-1.

95. Roberts E, Wong E, Svenneby G, Degener P. Sodium-dependent binding of GABA to mouse brain particles. *Brain Res* 1978;152:614–619, doi: http://dx.doi.org/10.1016/0006-8993(78)91194-8.

96. Reid MS, Hsu K Jr, Souza KH, Broderick PA, Berger SP. Neuropharmacological characterization of local ibogaine effects on dopamine release. *J Neural Transm* 1996;103:967–985, doi: http://dx.doi.org/10.1007/BF02917871.

97. Pimpinella G, Palmyr E. Interaction of β-carbolines with central dopaminergic transmission in mice: structure-activity relationships. *Neurosci Lett* 1995;189:121–124, doi: http://dx.doi.org/10.1016/0304-3940(95)11460-D.

98. Cumming P, Vincent SR. Inhibition of histamine-N-methyltransferase (HNMT) by fragments of 9-amino-1,2,3,4-tetrahydroacridine (tacrine) and by β-carbolines. *Biochem Pharmacol* 1992;44:989–992, doi: http://dx.doi.org/10.1016/0006-2952(92)90133-4.

99. Airaksinen MM, Lecklin A, Saano V, Tuoministo I, Gynther J. Tremorgenic effect and inhibition of tryptamine and serotonin receptor binding by β-carbolines. *Pharmacol Toxicol* 1987;50:5–8, doi: http://dx.doi.org/10.1111/j.1600-0773.1987.tb01711.x.

100. Miralles A, Esteban S, Sastre-Coll A, Moranta D, Asensio VJ, Garcia-Sevilla JA. High-affinity binding of β-carbolines to imidazoline I1 receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain. *Eur J Pharmacol* 2005;518:234–242, doi: http://dx.doi.org/10.1016/j.ejphar.2005.06.023.

101. Wiklund I, Sjöblad B, Björklund A. Morphological and functional studies on the serotoninergic innervation of the inferior olive. *J Physiol (Paris)* 1981;77:183–186.

102. Sjöblad B, Björklund A, Wiklund L. The indolaminergic innervation of the inferior olive. 2. Relation to harmaline induced tremor. *Brain Res* 1977;131:23–37, doi: http://dx.doi.org/10.1016/0006-8993(77)90026-9.

103. Costall B, Kelly DM, Naylor RJ. The importance of 5-hydroxytryptamine for the induction of harmaline tremor and its antagonism by dopaminergic agonists assessed by lesions of the midbrain raphe nuclei. *Eur J Pharmacol* 1976;35:109–119, doi: http://dx.doi.org/10.1016/0044-2996(76)90305-8.

104. Welsh JP, Chang B, Menaker ME, Aicher SA. Removal of the inferior olive abolishes myoclonic seizures associated with a loss of olivary serotonin. *Neuroscience* 1998;82:879–897, doi: http://dx.doi.org/10.1016/S0306-4522(97)00297-2.

105. Mehta H, Saravanan KS, Mohanakumar KP. Serotonin synthesis inhibition in olivo-cerebellar system attenuates harmaline-induced tremor in Swiss albino mice. *Behav Brain Res* 2003;145:31–36, doi: http://dx.doi.org/10.1016/S0166-4328(03)00094-9.

106. Arshadullien M, Kadassah S, Al Deeb S, Al Moutaery K, Tariq M. Exacerbation of harmaline-induced tremor by imipramine. *Pharmacol Biochem Behav* 2005;81:9–14, doi: http://dx.doi.org/10.1016/j.pbb.2005.01.014.

107. Arshadullien M, Al Kadassah S, Biary N, Al Deeb S, Al Moutaery K, Tariq M. Citalopram, a selective serotonin reuptake inhibitor augments harmaline-induced tremor in rats. *Behav Brain Res* 2004;153:15–20, doi: http://dx.doi.org/10.1016/j.bbr.2003.10.035.

108. Yamazaki M, Ikeda Y, Ishikawa M, Inagaki G, Tanaka C. Inhibition of harmaline induced tremor by L-3,4-dihydroxyphenylserine, an L-norepinephrine precursor. *Nippon Yakurigaku Zasshi* 1976;72:363–369, doi: http://dx.doi.org/10.1016/j.jpjjp.1976.02.363.

109. Yamazaki M, Tanaka C, Takaori S. Significance of central noradrenergic system on harmaline induced tremor. *Pharmacol Biochem Behav* 1979;10:421–427, doi: http://dx.doi.org/10.1016/0031-0634(79)90207-7.
110. Kolasiewicz W, Kuter K, Nowak P, Pastuszka A, Ossowska K. Lesion of the cerebellar noradrenergic innervation enhances the harmaline-induced tremor in rats. *Cerebellum* 2011;10:267–280, doi: http://dx.doi.org/10.1007/s12311-011-0250-9.

111. Cox B, Poskonjak D. An investigation of the tremorgenic actions of harmine in the rat. *Eur J Pharmacol* 1971;16:39–45, doi: http://dx.doi.org/10.1016/0014-2999(71)90054-9.

112. Kulkarni SK, Kaul PN. Modification by levo-propranolol of tremors induced by harmine in mice. *Experientia* 1979;35:1627–1628, doi: http://dx.doi.org/10.1007/BF01552322.

113. Paul V. Involvement of β2-adrenoceptor blockade and 5-hydroxytryptamine mechanism in inhibition of harmaline-induced tremors in rats. *Eur J Pharmacol* 1986;122:111–115, doi: http://dx.doi.org/10.1016/0014-2999(86)90165-2.

114. Niespodziany I, Klitgaard H, Margineanu D. Effects of brivaracetam (UCB 34714) on harmaline-induced electrophysiological changes in rat inferior olive neurons. *Eur J Pharmacol* 1986;122:111–115, doi: http://dx.doi.org/10.1016/0014-2999(86)90165-2.

115. Wood PI, Richard JW, Pilapil C, Nair NP. Agonists of excitatory amino acids and cyclic guanosine monophosphate in cerebellum. *Neuropharmacology* 1982;21:1235–1238, doi: http://dx.doi.org/10.1016/0028-3908(82)90126-3.

116. Koller WC. Ineffectiveness of phenoxybenzamine in essential tremor. *J Neurol Neurosurg Psychiatry* 1986;49:222, doi: http://dx.doi.org/10.1136/jnnp.49.2.222-a.

117. Elden F, Loschmann PA, Wullner U, Turski I, Klockgether T. Effects of 7-nitroindazole, NG-nitro-L-arginine, and D-CPPE1 on harmaline-induced postural tremor, N-methyl-D-aspartate-induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions. *Eur J Pharmacol* 1996;299:9–16, doi: http://dx.doi.org/10.1016/0014-2999(95)00795-4.

118. Paterson NE, Malekiani SA, Foreman MM, Olivier B, Hanania T. Pharmacological characterization of harmaline-induced tremor activity in mice. *Eur J Pharmacol* 2009;616:73–80, doi: http://dx.doi.org/10.1016/j.ejphar.2009.05.031.

119. Du W, Harvey JA. Harmaline-induced tremor and impairment of learning are both blocked by dizocilpine in the rabbit. *Brain Res* 1997;745:183–188, doi: http://dx.doi.org/10.1016/S0006-8993(96)01148-1.

120. Iseri PK, Karson A, Gullu KM et al. The effect of memantine in harmaline-induced tremor and neurodegeneration. *Neuropharmacology* 2011;61:715–723, doi: http://dx.doi.org/10.1016/j.neuropharm.2011.03.015.

121. Handforth A, Bordelon Y, Frucht SJ, Quesada A. A pilot efficacy and tolerability trial of memantine for essential tremor. *CNS Neuropharmacology* 2010;33:222–226, doi: http://dx.doi.org/10.1007/WMN.0b013e3181ebd109.

122. Mignani S, Bohme GA, Birraux G et al. 9-Carboxymethyl-5H,10H-imidazo[1,2-a]quinoxaleno[1,2-c]pyrazin-4-one-2-carboxylic acid (RPR117824): selective anticonvulsant and neuroprotective AMPA antagonist. *Bioorg Med Chem* 2002;10:1627–1637, doi: http://dx.doi.org/10.1016/S0968-0896(01)00431-X.

123. Kolasiewicz W, Kuter K, Wardas J, Ossowska K. Role of the metabotropic glutamate receptor subtype 1 in the harmaline-induced tremor in rats. *J Neural Transm* 2009;116:1059–1063, doi: http://dx.doi.org/10.1007/s00702-009-0254-5.

124. Shinozaki H, Hirate K, Ishida M. Further studies on quantification of drug-induced tremor in mice: effects of antitremorgenic agents on tremor frequency. *Exp Neurol* 1985;88:303–315, doi: http://dx.doi.org/10.1016/0014-4886(85)90193-1.

125. Tariq M, Arshaduddin M, Biary N, Al Moutaery K, Al Deeb S. Baclofen attenuates harmaline induced tremors in rats. *Neurosci Lett* 2001;312:79–82, doi: http://dx.doi.org/10.1016/S0304-3900(01)02166-8.

126. Meert TF. Pharmacological evaluation of alcohol withdrawal-induced inhibition of exploratory behaviour and supersensitivity to harmine-induced tremor. *Alcohol Alcohol* 1994;29:91–102.

127. Rappaport MS, Gentry RT, Schneider DR, Dole VP. Ethanol effects on harmaline-induced tremor and increase of cerebellar cyclic GMP. *Life Sci* 1984;34:49–56, doi: http://dx.doi.org/10.1016/0024-3205(84)90329-1.

128. Rogers J, Madamba SG, Staunton DA, Siggins GR. Ethanol increases single unit activity in the inferior olivary nucleus. *Brain Res* 1986;22:383–262.

129. Garbouy Y, Welsh JP. Systemic ethanol induces inferior olive synchrony and oscillation in vivo. *Neurosci Lett* 2000;34:735–738.

130. De Ryck M, Matagne A, Kendu B, Michel P, Klitgaard H. Contrasting effects of UCB 34714 and drugs for essential tremor on harmaline-induced elicited versus spontaneous tremor and sedation in rats. *Mov Disord* 2004;19:8443.

131. Handforth A, Martin FC, Kang GA, Vaneck Z. Zonisamide for essential tremor: an evaluator-blinded study. *Mov Disord* 2009;24:437–440, doi: http://dx.doi.org/10.1002/mds.22418.

132. Stohr T, Lekieffre D, Freitag J. Lacosamide, the new anticonvulsant, effectively reduces harmaline-induced tremors in rats. *Eur J Pharmacol* 2008;589:114–116, doi: http://dx.doi.org/10.1016/j.ejphar.2008.06.038.

133. Girone N, Pagonabarraga J, Pascual-Sedano B, Kulisevska Y. Lacosamide, another therapeutic failure in essential tremor: an open-label trial. *Mov Disord* 2011;26:183–184, doi: http://dx.doi.org/10.1002/mds.23296.

134. Ebble RJ, Biondi DM, Ascher S, Wiegan F, Hullman J. Carisbamate in essential tremor: brief report of a proof of concept study. *Mov Disord* 2010;25:634–638, doi: http://dx.doi.org/10.1002/mds.22872.

135. Martin FC, Handforth A. Carbocoxolone and melofloxone suppress tremor in the harmaline mouse model of essential tremor. *Mov Disord* 2006;21:1641–1649, doi: http://dx.doi.org/10.1002/mds.20940.

136. Zappala A, Parenti R, La Delia F, Cicirata V, Cicirata F. Expression of connexin57 in mouse development and in harmaline-tremor model. *Neuroscience* 2010;171:1–11, doi: http://dx.doi.org/10.1016/j.neuroscience.2010.09.010.

137. Sinton CM, Krosser BI, Walton KD, Llináis RR. The effectiveness of different isomers of octanol as blockers of harmaline-induced tremor. *Pharmacol Anthract* 1999;41:31–36, doi: http://dx.doi.org/10.1007/BF00356523.

138. Handforth A, Homanics GE, Covey DF et al. T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. *Neuropharmacology* 2010;59:380–387, doi: http://dx.doi.org/10.1016/j.neuropharm.2010.05.012.

139. Quesada A, Bui PH, Homanics GE, Hankinson O, Handforth A. Comparison of mibebradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor. *Eur J Pharmacol* 2011;659:30–36, doi: http://dx.doi.org/10.1016/j.ejphar.2011.01.004.
140. Bui PH, Quesada A, Handforth A, Hankinson O. The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil. Drug Metab Dispos 2008;36:1291–1299, doi: http://dx.doi.org/10.1124/dmd.107.020115.

141. Al-Deeb S, Al-Moutaery K, Arshaduddin M, Biary N, Tariq M. Effect of acute caffeine on severity of harmaline induced tremor in rats. Neurosci Lett 2002;325:216–218, doi: http://dx.doi.org/10.1016/S0304-3940(02)00042-3.

142. Biary N, Arshaduddin M, Al Deeb S, Al Moutaery K, Tariq M. Effect of lidocaine on harmaline-induced tremors in the rat. Pharmacol Biochem Behav 2000;65:117–121, doi: http://dx.doi.org/10.1016/S0091-3057(99)00175-6.

143. Berti F, Fano M, Folco GC, Longiave D, Omini C. Inhibition of harmaline induced tremors by 16 (S)-16-methyl PGE2 in different mammalian species: a correlation with central cyclic nucleotides and prostaglandins. Prostaglandins 1978;15:867–874, doi: http://dx.doi.org/10.1016/0090-6980(78)90153-3.

144. Shuto H, Kataoka Y, Kanaya A, Matsumaga K, Sueyasu M, Oishi R. Enhancement of serotonergic neural activity contributes to cyclosporine-induced tremors in mice. Eur J Pharmacol 1998;341:33–37, doi: http://dx.doi.org/10.1016/S0014-2999(97)01441-6.

145. Zoethout RW, Iannone R, Bloem BR et al. The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol. J Psychiatr Pharmacol 2012;26:292–302, doi: http://dx.doi.org/10.1177/0269881111398685.

146. Scarmeas N, Louis ED. Mediterranean diet and essential tremor. A case-control study. Neuroepidemiology 2007;29:170–177, doi: http://dx.doi.org/10.1159/000111579.

147. Louis ED, Faust PL, Vonsattel JP. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain 2007;130:3297–3307, doi: http://dx.doi.org/10.1093/brain/awm266.

148. Kronenbuerger M, Gerwig M, Brod B, Block F, Timmann D. Eyeblink conditioning is impaired in subjects with essential tremor. Brain 2007;130:1538–1551, doi: http://dx.doi.org/10.1093/brain/awm081.

149. Hallett M, Dubinsky RM. Glucose metabolism in the brain of patients with essential tremor. J Neurol Sci 1993;114:45–48, doi: http://dx.doi.org/10.1016/0022-510X(93)90047-3.

150. Wills A, Jenkins IH, Thompson PD, Findley LJ, Brooks DJ. Red nuclear and cerebellar but no olivary activation associated with essential tremor: a positron emission tomographic study. Ann Neurol 1994;36:636–642, doi: http://dx.doi.org/10.1002/ana.410360515.

151. Boecker H, Wills A, Ceballos-Baumann A et al. The effect of ethanol on alcohol-responsive essential tremor: a positron emission tomography study. Ann Neurol 1996;39:650–658, doi: http://dx.doi.org/10.1002/ana.410390515.

152. Shill HA, Bushara KO, Mari Z, Reich M, Hallett M. Open-label dose-escalation study of oral 1-octanol in patients with essential tremor. Neurology 2004;62:2320–2322, doi: http://dx.doi.org/10.1212/WNL.62.12.2320.

153. Nahab FB, Wittevrongel I, Ippolito D et al. An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor. Neurotherapeutics 2011;8:753–762, doi: http://dx.doi.org/10.1007/s13311-011-0045-1.

154. Handforth A, Martin FC. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord 2004;19:1215–1221, doi: http://dx.doi.org/10.1002/mds.20147.

155. Frucht SJ, Houghton WC, Bordelon Y, Greene PE, Louis ED. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 2005;65:1967–1969, doi: http://dx.doi.org/10.1212/01.wnl.0000189670.38576.bd.